BLOGIR-3, tablets 5 mg 30 pcs

How to take, the dosage

Orally, regardless of meals. It is necessary to open the blister carefully and take out the tablet without breaking it. The tablet for dissolution is placed on the tongue, where it dissolves, and then it is swallowed with saliva without drinking water or other liquids. The tablet should be taken immediately after opening the blister.

Adults and teenagers over 12 years old: 1 tablet for dissolution (5 mg) 1 time per day for reduction of symptoms of allergic rhinitis (including seasonal and year-round allergic rhinitis) and urticaria.

In seasonal (intermittent) allergic rhinitis (with symptoms lasting less than 4 days per week or less than 4 weeks per year) the course of the disease should be evaluated. In case of symptoms disappearance the drug shall be stopped, in case of recurrent symptoms the drug administration shall be renewed.

In case of year-round (persistent) allergic rhinitis (in the presence of symptoms lasting for more than 4 days a week or more than 4 weeks a year) the drug shall be taken during the whole period of allergen exposure.

Interaction

In multiple co-administration of desloratadine with ketoconazole, erythromycin, azithromycin, fluoxetine and cimetidine no clinically significant changes in plasma concentrations of desloratadine were found. BLOGIR-3® does not increase the effect of alcohol on the central nervous system. Food intake has no effect on the effectiveness of the drug.

.

Special Instructions

With caution desloratadine is prescribed in severe renal failure.

Influence on driving and operating machinery

There have been no adverse effects on driving or operating complex technical devices.

Contraindications

hypersensitivity to desloratadine, other drug components or loratadine;

phenylketonuria;

pregnancy;

breastfeeding period;

under 12 years of age.

With caution: severe renal insufficiency; seizures in anamnesis.

Side effects

The frequency of adverse reactions is classified according to the recommendations of the World Health Organization: very common – at least 10%; common – at least 1%, but less than 10%; infrequent – at least 0.1%, but less than 1%; rare – at least 0.01%, but less than 0.1%; very rare – less than 0.01%, including individual reports.

The most common adverse effects (>1/100 to <1/10): fatigue, dry mouth, and headache.
Very rarely (<1/10,000) the following unwanted effects were noted:

Central nervous system: hallucinations, dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures.
Cardiovascular system: tachycardia, palpitations.

Digestive system: abdominal pain, nausea, vomiting, dyspepsia, diarrhea.

Liver and biliary tract: increased liver transaminase activity, increased concentration of bilirubin, hepatitis.

Musculoskeletal system: myalgia.

Immune system: anaphylaxis, angioneurotic edema, dyspnea, itching, rash, including urticaria, photosensitization.
If any of the side effects specified in the instructions are aggravated, or if you notice any other side effects not specified in the instructions, inform the doctor.

Overdose

In clinical trials when using desloratadine in doses up to 45 mg (9 times the therapeutic dose) no clinically significant adverse effects were observed.

Treatment: In case of overdose standard measures are taken to remove the active substance from the gastrointestinal tract. Symptomatic and supportive therapy is recommended.
Desloratadine is not excreted by hemodialysis, the effectiveness of peritoneal dialysis has not been established.

Pregnancy use

The use of the drug BLOGIR-3® during pregnancy is contraindicated due to the lack of clinical data on the safety of its use during this period.
Desloratadine is excreted with the breast milk, so the use of the drug during breast-feeding is contraindicated.

Similarities

Lordestin, Erius, Dezal, Desloratadine, BLOGIR-3, Ezlor